Clinical features and outcomes of MEN2A with RET codon 634 pathogenic variants
Abstract
Background: Germline RET codon 634 pathogenic variants (PVs) are at high-risk for early-onset medullary thyroid carcinoma (MTC), but prior reports suggest that RET p.C634R PV may confer a more aggressive phenotype.
Methods: We compared MEN2A phenotype and MTC outcomes with germline RET p.C634R vs other RET p.C634X PVs. We conducted a retrospective single-center cohort study of patients harboring a germline RET p.C634 PV, enrolled in the MTC Collaborative Registry (MTCCoRe) and seen at least once between May 2012 and May 2024.
Results: One hundred and thirty-five patients included: p.C634R (n = 60) and other p.C634X variants (n = 75). The p.C634R PV was associated with higher penetrance of pheochromocytoma (PHEO) (67% vs 37%, P < .001) and primary hyperparathyroidism (PHPT) (30% vs 15%, P = .036). Prevalence of MTC (87% vs 80%, P = .362), cutaneous lichen amyloidosis (17% vs 9% P = .296), and median age at initial thyroidectomy (18 vs 20 years, P = .479) did not differ significantly between groups. Medullary thyroid carcinoma characteristics, including stage, multifocality, extrathyroidal extension, vascular invasion, lymph node metastases, and distant metastases, were comparable. There were no significant differences in disease-free survival, overall survival, or distant metastasis-free survival for MTC. Disease status at last follow-up also was similar between p.C634R and other p.C634X PVs: no evidence of disease in 43% vs 62% (P = .059), biochemical evidence of disease in 25% vs 17% (P = .226), and structural evidence of disease in 27% vs 20% (P = .298).
Conclusion: In this large single-center cohort, germline RET p.C634R was associated with a higher penetrance of PHEO and PHPT but did not increase MTC aggressiveness or worsen clinical outcomes compared with other RET p.C634 PVs.
Related
- Associations of Pathogenic Sequence Variants and Copy Number Variants with Cardiovascular and Major Clinical Outcomes in Adults with Congenital Heart Disease
- A case of renal hypouricemia type 1 associated with compound heterozygous URAT1/SLC22A12 variants A209V and F379L: clinical evidence for their pathogenic significance
- Male breast cancer: clinicopathological features and prevalence of germline pathogenic variants
- Identification of two pathogenic guanidinoacetate methyltransferase variants in patients with intellectual disability: clinical and molecular insights
- Clinical deep sequencing to diagnose pathogenic mosaic variants in malformations of cortical development and epilepsy
BibTeX
@article{hamidi2026clinical,
title = {{Clinical features and outcomes of MEN2A with RET codon 634 pathogenic variants}},
author = {Sarah Hamidi and Steven G Waguespack and Naifa L Busaidy and Paul H Graham and Mouhammed A Habra and Nancy D Perrier and Steven I Sherman and Catherine B Skefos and Julie Ann Sosa and Anita K Ying and Mark E Zafereo and Elizabeth G Grubbs and Mimi I Hu},
journal = {Journal of the Endocrine Society},
year = {2026},
month = oct,
doi = {10.1210/jendso/bvag254},
url = {https://europepmc.org/article/PMC/PMC13728336},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical features and outcomes of MEN2A with RET codon 634 pathogenic variants
AU - Sarah Hamidi
AU - Steven G Waguespack
AU - Naifa L Busaidy
AU - Paul H Graham
AU - Mouhammed A Habra
AU - Nancy D Perrier
AU - Steven I Sherman
AU - Catherine B Skefos
AU - Julie Ann Sosa
AU - Anita K Ying
AU - Mark E Zafereo
AU - Elizabeth G Grubbs
AU - Mimi I Hu
PY - 2026
DA - 2026/10/31
JO - Journal of the Endocrine Society
DO - 10.1210/jendso/bvag254
UR - https://europepmc.org/article/PMC/PMC13728336
AB - Background: Germline RET codon 634 pathogenic variants (PVs) are at high-risk for early-onset medullary thyroid carcinoma (MTC), but prior reports suggest that RET p.C634R PV may confer a more aggressive phenotype. Methods: We compared MEN2A phenotype and MTC outcomes with germline RET p.C634R vs other RET p.C634X PVs. We conducted a retrospective single-center cohort study of patients harboring a germline RET p.C634 PV, enrolled in the MTC Collaborative Registry (MTCCoRe) and seen at least once between May 2012 and May 2024. Results: One hundred and thirty-five patients included: p.C634R (n = 60) and other p.C634X variants (n = 75). The p.C634R PV was associated with higher penetrance of pheochromocytoma (PHEO) (67% vs 37%, P < .001) and primary hyperparathyroidism (PHPT) (30% vs 15%, P = .036). Prevalence of MTC (87% vs 80%, P = .362), cutaneous lichen amyloidosis (17% vs 9% P = .296), and median age at initial thyroidectomy (18 vs 20 years, P = .479) did not differ significantly between groups. Medullary thyroid carcinoma characteristics, including stage, multifocality, extrathyroidal extension, vascular invasion, lymph node metastases, and distant metastases, were comparable. There were no significant differences in disease-free survival, overall survival, or distant metastasis-free survival for MTC. Disease status at last follow-up also was similar between p.C634R and other p.C634X PVs: no evidence of disease in 43% vs 62% (P = .059), biochemical evidence of disease in 25% vs 17% (P = .226), and structural evidence of disease in 27% vs 20% (P = .298). Conclusion: In this large single-center cohort, germline RET p.C634R was associated with a higher penetrance of PHEO and PHPT but did not increase MTC aggressiveness or worsen clinical outcomes compared with other RET p.C634 PVs.
SN - 2472-1972
ER -